HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.
Upcoming Q3 earnings on Nov 12 plus a recent bullish analyst price-target hike are the dominant near-term catalysts; insider selling is a minor offsetting negative.
Heartflow will report Q3 2026 financial results after market close on Nov 12, 2026, with a conference call at 4:30 p.m. ET. Given the prior quarter's 48% revenue growth and raised full-year guidance, this is the key near-term binary event; results and guidance could drive significant volatility.
Heartflow Investor Relations (GlobeNewswire)Piper Sandler lifted its Heartflow price target to $64 from $45 while maintaining an Overweight rating, citing a durable competitive moat in FFRct and plaque analysis. The bullish analyst action drove a 9.1% single-day rally on Oct 20 and reinforces positive near-term momentum.
Quiver QuantitativeInsider Campbell Rogers sold 23,933 shares at an average of $55.01 (~$1.32M), cutting his stake by 24.58% to 73,453 shares, under a pre-arranged Rule 10b5-1 plan. The sale occurred near the 52-week high and follows prior sales in August and September, which could weigh modestly on sentiment.
MarketBeat